Hypnotic & Antiepileptic..Part 2 References

Discussion of the Paper

Dr. Cornwell: Why did you use weekly doses of CBD for your
insomnia study? Was there any differential effect in terms of improvement
in sleep for the 7 nights between the doses?
Dr. Carlini: We used single doses of CBD 40, 80, and 160 mg at
weekly intervals mainly because we had only a very small supply of CBD. I
have no data on differential effects on sleep since the patients were
interviewed only at weekly intervals.
Dr. Benowitz: We studied 10 patients receiving 600 mg of CBD per
day for up to 12 days (Benowitz, NL, et al. Clin Pharmacol Therap. 1980;
28: 115-120) We found no psychophysiological, sedative hypnotic, nor EEG
effects. Consistent with findings from experiments in animals, barbiturate
metabolism was inhibited (35-40% reduction of hexobarbital clearance).
Is it possible that some of the hypnotic and anticonvulsant effects of CBD
might be due to inhibition of metabolism of co-administered anticonvulsant
drugs?
Dr. Carlini: That is a real possibility, since all patients were
also receiving phenobarbital, mehpobarbital, or phenytoin. The first
hypothesis would be that CBD interferes with metabolism, potentiating the
action of these drugs as you suggest. The second of course would be that
CBD had an action by itself. We have no data to address these two
possibilities.
Dr. Karler: The sedative effects appear to be real, because some
normal volunteers were sedated by CBD in the absence of any coexisting drug
therapy. Why is it, however, that Dr. Benowitz did not see sedative
effects in his patients? Was that due to a dose-differential?
Dr. Benowitz: In our study, 600 mg a day was administered in
divided 100 mg doses.

References

1. Carlini EA. Maconha (Cannabis sativa): da erva do diabo a
medicamento do establishment? Ciencia e Cultura. 1980; 32: 684-690.
2. Mechoulam R, Carlini EA. Toward drugs derived From Cannabis.
Naturwissenschaften. 1978; 65: 174-179.
3. Winek CL. Some historical aspects of marihuana. Clin Toxicol.
1977; 10: 243-253.
4. Consroe PF, Man DP. Effects of Delta-8-and
Delta-9-tetrahydrocannabinol on experimentally induced seizures. Life Sci.
1973; 13: 429-439.
5. Consroe PF, Man DP, Chin L, Piccioni AL. Reduction of
audiogenic seizure by Delta-8-and-Delta-9-tetrahydrocannabinols. J Pharm
Pharmacol. 1973; 25: 764-765.
6. Cousens K, Di Mascio A. Delta-9-THC as an hypnotic. An
experimental study of 3 dose levels. Psychopharmacology. 1973; 33:
355-364.
7.Gildea ML, Bourn WM. The effect of delta-9-tetrahydrocannabinol
on barbiturate withdrawal convulsions in the rat. Life Sci. 1977; 21:
829-832.
8. Karler R, Cely W, Turkanis SA. Anti-convulsant activity of
delta-9-tetrahydrocannabinol and its 11-hydroxy and 8a,
11-hydroxy-metabolites in the frog. Res Commun Chem Pathol Pharmacol.
1974; 9: 441-452.
9. Sofia RD, Barry H III. Comparative activity of THC,
diphenylhydantoin, phenobarbital and chlordiazepoxide on electroshock
seizure threshold in mice. Arch Int Pharmacodyn Therap. 1977; 228:
73-78.
10. Sofia RD, Solomon TA, Barry H III. Anticonvulsant activity of
delta-9-THC compared to three other drugs. Eur J Pharmacol. 1976; 35:
7-16.
11. Wada JA, Wake A, Sato M, Corcoran ME. Antiepileptic and
prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.
Epilepsia. 1975; 16: 503-510.
12. Consroe P, Martin P, Eisenstein D. Anticonvulsant drug
antagonism of delta-9-THC-induced seizures in rabbits. Res Commun Chem
Pathol Pharmacol. 1977; 16: 1-13.
13. Craigmill AL. Cannabinoids and handling-induced convulstions.
Res Commun Psychol Psychiat Behavior 1979; 4: 51-63.
14. Feeney DM. Marihuana and epilepsy: paradoxical
anticonvulsant and convulsant effects. In: Nahas GG, Paton WDM, eds.
Marihuana, Biological Effects. Advances in the Biosciences 22/23.
Oxford: Pergamon Press; 1979: 643-657.
15. Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of
four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol.
1975; 12: 1-15.
16. Savaki HE, Cunha J, Carlini EA, Kephalas TA. Pharmacological
activity of three fractions obtained by smoking cannabis through a water
pipe. Bull Narcotics. 1976; 28: 49-56.
17. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Cannabidiol
and Cannabis sativa extract protect mice and rats against convulsive
agents. J Pharm Pharmacol. 1973; 25: 664-665.
18. Consroe P, Wolkin A. Cannabidiol--antiepileptic drug
comparisons and interactions in experimentally induced seizures in rats. J
Pharmacol Exp Therap. 1977; 201: 26-32.
19. Karler R, Cely W, Turkanis SA. The anticonvulsant activity of
cannabidiol and cannabinol. Life Sci. 1973; 13: 1527-1531.
20. Karler R, Turkanis SA. Subacute cannabinoid treatment:
anticonvulsant activity and withdrawal excitability in mice. Br J
Pharmacol. 1980; 68: 479-484.
21. Monti JM. Hypnotic-like effect of cannabidiol in the rat.
Psychopharmacology. 1977; 55: 263-265.
22. Carlini EA, Masur J, Magalhaes CCPB, Possivel efeito
hipnotico do canabidiol no ser humano. Estudo preliminar. Ciencia e
Cultura. 1979: 31: 315-322.
23. Consroe P, Carlini EA, Zweicker AP, Lacerda LA. Interaction
of cannabidiol and alcohol in humans. Psychopharmacology. 1979: 45-50.
24. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C,
Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic Administration of
cannabidiol to healthy volunteers and epileptic patients. Pharmacology.
1980; 21: 175-185.
25. Mincis M, Pfeferman A, Guimaraes RX, Ramos OL, Zukerman E,
Karniol IG, Carlini EA. Administracao cronica de canabidiol em seres
humanos Rev Ass Med Bras. 1973; 19: 185-190.
26. Bloomfield SS, Tetreault L, Lafreniere B, Bordeleau JM. A
method for the evaluation of hypnotic agents in man. Comparative hypnotic
effects of secobarbital, methaqualone and placebo in normal subjects and in
psychiatric patients. J Pharmacol Exp Therap. 1967; 156: 375-382.
27. Davis C, Levine S. A controlled comparison of nitrazepam
("Mogadon") with sodium amylobarbitone as a sleep inducing agent. Br. J
Psychiat. 1967; 113: 1005-1008.
28. Haider I. A double-blind controlled trial of an
nonbarbiturate hypnotic--nitrazepam. Br J Psychiat. 1968; 114: 337-343.

29. Hartman E, Chung R, Chien CC. L-Tryptophane and sleep.
Psychopharmacology. 1971; 19: 114-127.
30. Rickels K. Clinical evaluation of hypnotic agents in
outpatients. In: Kagan F, Harwood T, Rickels K, Rudzik AD, Sorer H, eds.
Hypnotics--Methods of Development and Evaluation. New York: Spectrum
Publications; 1975.
31. Chesher GB, Jackson DM. Anticonvulsant-effects of
cannabinoids in mice. Drug interactions with cannabinoids and cannabinoid
interactions with phenytoin. Psychopharmacology. 1974; 37: 255-264.
32. Chesher GB, Jackson DM, Malor Rm. Interaction of
Delta-9-tetrahydrocannabinol and cannabidiol in protecting mice from
electrically induced convulsions. J Pharm Pharmacol. 1975; 27: 608-609.
33. Dalton WS, Martz R, Rodda BE, Lemberger L, Forney RB.
Influence of cannabidiol on secobarbital effects and plasma kinetics. Clin
Pharmacol Therap. 1976; 20: 695-700.
34. Tamir I, Mechoulam R, Meyer AY. Cannabidiol and phenytoin: a
structural comparison. J Med Chem. 1980; 23: 220-223.

PREVIOUS INDEX HOME